Completed PHASE1 INTERVENTIONAL 3-arm NCT02063360

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Open-Label, Single-Sequence Study to Evaluate the Pharmacokinetic Interaction of BMS-663068 With Darunavir/Ritonavir and/or Etravirine in Healthy Subjects

Sponsor: GlaxoSmithKline

Conditions Infection, Human Immunodeficiency Virus

Interventions BMS-663068 Darunavir (DRV) Etravirine (ETR) Ritonavir (RTV)

Updated 7 times since 2017 Last updated: Aug 7, 2017 Started: Feb 1, 2014 Primary completion: May 1, 2014 Completion: May 13, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02063360, this PHASE1 trial focuses on Infection, Human Immunodeficiency Virus and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Apr 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Apr 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
ViiV Healthcare

Data source: ViiV Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.